
    
      The aim of this study is to evaluate patients converted to belatacept in combination with
      Mycophenolate Mofetil (MMF) with corticosteroids with respect to their DSA titer. Patients in
      this study will be converted from their calcineurin inhibitor (CNI) to belatacept from
      baseline in an attempt to down-modulate antibody production by B-cells. Dosing will be
      calculated per prescribing information for dosing maintenance phase (5mg per kg every 28
      days.
    
  